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Abstract
Background:
HIV antiretroviral therapy (ART) is associated with breast abnormalities in adults, 
especially efavirenz (EFV). Little is known about the prevalence of these adverse 
effects among adolescents receiving ART.
Methods:
A retrospective record review describing breast conditions in adolescents receiving 
ART at three facilities in Johannesburg, South Africa was conducted. Patients aged 
10-19 years who presented from 1 January to 31 December 2014 were included. 
Analyses were conducted to determine whether EFV use was associated with an 
increase in breast conditions.
Results:
A total of 631 patient records were reviewed, 37 (6%) had an abnormal breast event 
documented of whom 24/37 (65%) were male. Patients with abnormal breast 
conditions developed them 1.5 years later than patients with normal breast 
development (p<0.0005). Forty-one abnormal breast events were observed in thirty- 
seven patients with twenty being described as gynaecomastia or lipomastia (49%). 
44% had concurrent generalised lipodystrophy (n=19). Of those with an abnormal 
breast event, 71% of patients had CD4 counts >500 cells/pl and were virologically 
suppressed (n=29). Those on EFV had a significantly higher prevalence of breast 
abnormalities compared to other regimens (p=0.016) and all had been exposed to 
EFV before. No other ART drug was associated with breast abnormalities in this 
cohort. Sixteen patients had substitution of EFV and three breast events resolved 
once substituted from EFV.
Conclusion:
Six percent of patients had an abnormal breast condition in this study. Use of EFV 
and increasing age were associated with breast abnormalities in this population. 
Further research is needed to better understand this phenomenon.
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1. Background
Increasing numbers of HIV-infected children are entering into adolescence. Thus, 
ensuring appropriate care, including the recognition and management of co­
morbidities of HIV and the side effects of antiretroviral therapy (ART) is a vital aspect 
of HIV management. Increasing numbers of adolescents on ART, both male and 
female, are reporting abnormalities of their developing or, already developed, 
breasts.1
Adolescence is a time of profound physical development and is defined by the World 
Health Organisation as individuals aged 10 to 19 years.2 During this period, puberty 
leads to changes in previously childlike bodies, and breast development in girls, as 
well as in boys, is part of typical pubertal development.3-5 This development in girls 
is well described by the Tanner staging system.3 Here the development of a normal 
breast is described from the initial tiny breast bud to become a mature adult breast.3
One described problem of breast development in teenaged girls is breast 
hyperplasia.4 Breast hyperplasia or hypertrophy in adult women receiving efavirenz 
(EFV) has been described however the same condition is not well explored in 
adolescent girls.6 Juvenile breast hyperplasia is defined as the uncontrolled 
overgrowth of breast tissue that occurs in adolescents whose breasts develop 
normally during puberty, however fail to stop growing at the appropriate time.4
Tanner staging does not account for normal pubertal-related, physiological breast 
enlargement or gynaecomastia in boys.35 Gynaecomastia is defined as glandular 
proliferation causing enlargement of the male breast. Physiological gynaecomastia is 
described in three periods of male life: during the neonatal period, adolescence and 
in the latter years.5 In one large cross sectional study, physiological gynaecomastia
was shown to present in 4% of boys aged 10 to 19 years old.5 Physiological 
gynaecomastia may present in boys as young as 10 years old, however, the peak 
onset in adolescence is usually between 13 and 14 years old.5 The postulated cause 
for this is not known though hormonal fluctuations during adolescence may 
contribute.5 Causes of pathological gynaecomastia include medications, adrenal and 
testicular neoplasms, congenital syndromes such as Klinefelters and Peutz-Jeghers, 
hyperthyroidism and thyrotoxicosis, liver failure and cirrhosis, primary 
hypogonadism, congenital adrenal hyperplasia, androgen insensitivity, obesity and 
malnutrition.5
Pathological gynaecomastia in adolescence due to excess oestrogen caused by 
certain medications has been described.57 In particular, these are attributed to the 
use of medications for cardiovascular disorders (amiodarone and calcium channel 
blockers), asthma (theophylline), central nervous system disorders (phenytoin and 
tricyclic antidepressants), tuberculosis (isoniazid) and other infections (ketoconazole 
and metronidazole).7
Antiretrovirals, particularly EFV, have been shown to cause breast abnormalities in 
adults.68 The breast abnormalities attributed to antiretroviral therapy (ART) are 
divided into two classes: the first being lipomastia associated with lipodystrophy and 
the second, breast enlargement in those patients who have no evidence of 
lipodystrophy.8 Little is known about the prevalence of these adverse effects in 
adolescents receiving ART.
Lipodystrophy can be caused by different ARVs particularly nucleotide reverse 
transcriptase inhibitors (NRTI) such as stavudine (D4T) and zidovudine (AZT).9 The 
role of efavirenz (EFV) and lopinavir (LPV) remains disputed however in some cases
these drugs have been linked to the development of lipodystrophy.9 Sonography 
may be used to differentiate between lipomastia related to lipodystrophy and true 
gynaecomastia in males on ART.8 Breast ultrasonography was shown to be a 
sensitive method of distinguishing an increase in ductal tissue and periductal stroma 
associated with gynaecomastia from the predominantly fatty accumulation seen in 
lipomastia.8
It has been shown that EFV, a non-nucleotide reverse transcriptase inhibitor 
(NNRTI), is capable of activating oestrogen receptors and causing growth of breast 
tissue.10 The effects of this oestrogen receptor activation in a child or an adolescent 
undergoing puberty are largely unknown.
Research done on the UK and Ireland’s national Collaborative HIV Paediatric Study 
(CHIPS) cohort, studied the frequency, cause and management of severe 
gynaecomastia.1 In that cohort, 3% experienced gynaecomastia (n=56/1873) of 
which 10 patients were reported to be severe.1 The median age of onset for these 
patients was 13.5 years and they had been on their current ART regimen for a 
median of 27.5 months.1 Half of the affected patients were receiving an NNRTI and 
the other half a Protease Inhibitor (PI), however all ten had previous exposure to 
EFV, didanosine (DDI) and D4T.1
Furthermore, a case study from South Africa described a further case of a 
prepubertal girl who developed pseudogynaecomastia four months after initiation 
onto EFV-based ART with full resolution of the breast enlargement following 
cessation of EFV.11
In another case of a 15 year old HIV infected boy, severe bilateral breast 
development occurred two years after changing to a regimen containing D4T, DDI
and EFV.12 He was virologically suppressed at the time.12 Regression of the breasts 
did not occur after drug substitution and a bilateral mastectomy was performed.12
This is in contrast to the findings in adults, which usually support a shorter temporal 
relationship of a few months to developing gynaecomastia or breast enlargement 
once starting a new EFV-containing regimen.613 In a case series originating in 
Bordeaux, France, two woman and four men experienced breast pain and/or 
enlargement within one to six months of switching to an EFV-based regimen.6 In all 
six patients hormone profiles were normal and they remained on EFV while in only 
one case did spontaneous regression occur.6 In the same study, 28.7% of the 258 
patients receiving ART were on EFV and, of these, 8,1% had experienced breast 
enlargement.6 This includes the six patients described above.
Another group in the United Kingdom suggest that gynaecomastia in HIV infected 
adults can be as a result of immune reconstitution inflammatory syndrome (IRIS).8 
IRIS is defined as a clinical syndrome consistent with an inflammatory process with 
evidence of an immune response which occurs usually within three months of ART 
initiation.14 IRIS generally occurs in a subset of HIV-infected individuals when ART is 
initiated at low CD4 counts and HIV viral replication is halted.1415 This leads to a 
patient‘s CD4 count increasing, causing an inflammatory reaction to previously 
undetected pathogens in their body.15 This inflammatory reaction was hypothesised 
to cause gynaecomastia in a small group of 15 patients where no association with 
EFV treatment was seen as patients were treated with different classes of ARVs.8 
Once full immune reconstitution had taken place, resolution of the gynaecomastia 
occurred in 80% of the patients.8
It has been hypothesised that many cases of gynaecomastia are caused by 
hypogonadism.16 A study performed at two HIV referral centres in Barcelona, Spain, 
suggested that most cases of gynaecomastia in HIV infected male patients occurred 
as a result of hypogonadism related to HIV infection itself rather than as an adverse 
effect of ARVs.16 The hypothesis was strengthened by the fact that both affected and 
control patients had a similar length of exposure to D4T, AZT and EFV, whereas the 
affected group had significantly lower free testosterone indices when compared to 
the control group (p=0.006).16 However the findings of other studies suggest no 
difference in the hormonal profiles of the participants.813 A limitation of this study 
was that hypogonadism was not uncommon in the control group which was not 
explained by the methodology of the study.16
Interventions for breast abnormalities in HIV infected adults differ according to the 
hypothesised cause. In the Spanish group who hypothesised, that gynaecomastia 
was secondary to hypogonadism, managing the hypogonadism was key.16 Patients 
with gynaecomastia had a mean free testosterone index of 42.6% compared to the 
controls with 58.1% (p=0.006).16 They described that most cases of gynaecomastia 
resolved spontaneously and, for those who did not resolve, intramuscular or 
transdermal testosterone was administered.16 The gynaecomastia response to the 
testosterone replacement are not described in the published study.16
If the hypothesis that EFV causes breast abnormalities by activating oestrogen 
receptors is accepted, then the use of anti-oestrogen drugs such as Tamoxifen and 
the substitution of EFV are recommended.510 In the child and adolescent cohort in 
the United Kingdom, optimal management of severe breast abnormalities ranged 
varied from an immediate ART substitution to differing periods of observation which 
led to a change in ART for most patients.1
No treatment was deemed necessary where IRIS was the accepted hypothesis.8 In 
the UK adult cohort, once the immune reconstitution had occurred and the cytokines 
began to fall, spontaneous resolution of the gynaecomastia was noted.8 Where fat 
accumulation as part of lipodystrophy was seen concurrently with breast 
enlargement, drug substitution of the PI was recommended.9 In most cases, this was 
not possible, and, even where possible, it was not highly successful.9 In these cases 
surgical intervention, with its accompanying risks, was seen as the only remaining 
option.9 There was, however, a risk of recurrence of fat accumulation in the breasts 
with up to a half of patients experiencing a recurrence within one to two years of 
surgical intervention.9
Therefore, the aim of this study was to establish the extent of breast abnormalities in 
adolescents receiving ART in South Africa and to determine whether there were 
associated ART drugs, co-morbidities, common investigations and prescribed 
interventions in this setting.
2. Methods
2.1. Record review and data extraction
Study Type:
A retrospective review of routinely collected medical records was performed at three 
public health facilities managing adolescent HIV patients in Johannesburg, South 
Africa.
Inclusion criteria:
In order for patients’ records to be eligible for review, they had to be aged 10 to 19 
years, on ART and had to have presented to their health facility during the study 
period, 1 January to 31 December 2014.
Exclusion Criteria:
Records that did not meet these criteria, or were not available on site (for example 
lost or archived files) were not included in the review.
Study Sample
All available files meeting the inclusion criteria were reviewed.
Data capture and storage:
For eligible files, information regarding patient’s demographic profiles and a brief 
ART history were captured. The current ART regimen during the study period was 
recorded where possible for all eligible records.
Patient records were then screened for mention of the words "breast”, 
"gynaecomastia” or "lipomastia”. For those with a recorded breast-related event, HIV 
information, both around the time of the breast event, as well as a comprehensive 
history of ART regimens was captured. A detailed clinical history around the time of 
the event as well as details of the actual breast condition were also captured.
The description of the breast as well as whether the breast changes were considered 
to be normal development or an abnormal condition were captured in freehand to 
ensure no important information was lost.
Data collection forms were developed specifically to extract all relevant information 
for this study from the existing clinical records. All recorded patient information was 
de-identified and given a study number to maintain confidentiality. A password 
protected linking file was kept. Study data was then managed using REDCap 
electronic data capture tools hosted at University of Witwatersrand.17
2.2. Outcome of Interest
The outcome of interest was whether an adolescent patient on ART had an 
abnormal breast event. For patient files with any breast event mentioned, the breast 
events were categorised as abnormal or normal. Abnormal events were defined prior 
to the study as being inclusive of descriptions of gynaecomastia, lipomastia, 
abnormal breast enlargement and breast lump. The "normal” breast cases were 
grouped together with those in which there was no mention of breast who were 
assumed to be developing normally as well.
Information from the records regarding whether an abnormal breast condition was 
investigated or intervened upon were analysed and the nature of the interventions for 
each abnormality were categorised. For those who received an ART drug 
substitution, the use of different drugs as well whether a particular drug substitution 
led to resolution of the breast problem was analysed.
2.3. Data collection: Patient demographic, HIV and breast-related clinical 
information
All eligible medical files were included in the data analysis. For all eligible records, 
demographic data were analysed. These included age (in years) at time of last visit
during study period, clinic where patient received treatment including the approved 
study sites of Alexandra Health Care Centre and University Clinic (Clinic A), Right to 
Care Paediatric HIV Clinic (Clinic B), Witkoppen Health and Welfare Centre (Clinic 
C) and sex of the patient. Patient ART history analysed included age (in years) at 
ART initiation, duration on ART at time of last visit during study period, and current 
regimen at time of last visit during study period. Table 1 shows the different ART 
drugs available in the public sector for use in children and adolescents in South 
Africa, the class to which each drug belongs and the associated adverse events.
Table 1: Individual antiretroviral drugs for paediatric and adolescent treatment in South Africa
A n tire tro v ira l C lass Form ulation A d verse  e ffects
A b a ca v ir (ABC ) NRTI S o lu tion  20m g/m l, T ab le ts  60 m g, 300 m g, A B C /3TC A B C  h ype rsens itiv ity  reaction
A ta za n a v ir (ATV) PI T ab le t 150m g, 200m g, 300m g Ind irect hype rb ilirub inaem ia , EC G  abnorm a lities
D arunav ir (DRV) PI Tab le ts  75m g, 150m g, 600m g H epatitis , R ashes
D idanos ine  (DDI) NRTI Tab le ts  25m g, 50m g, 100m g,C apsu le  250m g Lactic  A c idos is
E fav irenz (EFV) NN RTI C apsu les 50m g, 200m g, T ab le t 600m g P ers is ten t C N S tox ic ity , H epa to tox ic ity
E m tric itab ine  (FTC ) NRTI C o-fo rm ula ted  w ith  TD F  and T D F+ E F V Skin, hype rsens itiv ity  reactions
Lam ivud ine  (3TC) NRTI S o lu tion  10m g/m l, T ab le t 150m g, 300m g R are, Pure red cell aplasia
Lop inav ir/r (LPV/r) PI S o lu tion  80 /20m g/m l, T ab le ts  200 /50m g, 100/25m g G astro in testina l, D ys lip idaem ia , L ive r enzym e e levation
N evirap ine  (NVP) NN RTI S o lu tion  10m g/m l, T ab le t 200m g H epato tox ic ity , H ype rsens itiv ity  R eaction , C onvu ls ions
R ilp iv irine  (RPV) NN RTI T ab le t 25m g R ashes, L ive r Failure
R itonav ir (r) PI S o lu tion  80m g/m l, T ab le t 100m g G astro in testina l, H ype rlip idaem ia
S tavud ine  (D4T) NRTI S o lu tion  1m g/m l, C apsu le  15m g, 20m g, 30m g L ipodystrophy, Lactic  A c idos is , P eriphera l neu ropa thy
T en o fov ir (TD F) NRTI T ab le t 300m g, C o-fo rm u la ted  w ith  FTC and FTC + E FV A cu te  and ch ron ic  renal insu ffic iency
Z idovud ine  (AZT) NRTI S o lu tion  10m g/m l, T ab le ts  300m g, C o-fo rm u la ted  w ith  A Z T L ipodystrophy, A naem ia , N eu tropaen ia
Adapted from the National Consolidated Guidelines of the prevention of mother-to-child transmission of HIV (PMTCT) and the management of HIV in children, 
adolescents and adults and the Guidelines for the Management of HIV in Children, 2010 1819
Drugs not included in the national guidelines include darunavir and rilpivirine20 21
For each file, the current ART data was analysed by comparing whole regimens as 
well as the use of individual ART drugs prescribed. Table 2 shows the common ART 
regimens used in South Africa since the rollout of the national ART programme in 
2004.22 As can be seen in table 2, all regimens contain two NRTI drugs, with 
lamivudine or, its analogue emtricitabine, being present in all but two previously used 
second line regimens and Lamivudine Monotherapy (LM). All regimens also contain 
either a PI or an NNRTI with no recommended regimens containing both. LM 
contains neither a NNRTI nor a PI. Lamivudine Monotherapy (LM) is an alternative to 
a suppressive ART regimen and was often used as a holding regimen in this cohort.
All the drugs in the NRTI class were compared looking for the NRTI drugs that were 
most often prescribed in this cohort (excluding lamivudine, which is present in almost 
all prescribed ART regimens for children and adolescents).
The use of drugs in the NNRTI and PI classes in this cohort were compared. NNRTI 
and PI drugs are grouped together as usually only one drug from either class is 
present in a first or second line regimen at a time.
Table 2: ART regimens for paediatric and adolescent treatment in South Africa
R egim en Ind icated  ages Ind ication G uide lines
D 4T + 3TC  + LP V /r 6 m onths -  3 years F irs t line 2004 -  2010
D 4T + 3TC  + EFV > 3 years  (and > 10kg) F irs t line 2004 -  2010
A B C  + 3TC  + LP V /r <3 years F irs t line 2009 -  to  date
A B C  + 3TC  + EFV 3 - 14 years F irs t line 2009 -  to  date
TD F  + FTC + EFV > 15 years F irs t line 2015 -  to  da te *
A Z T  + DDI + NVP 6 m onths - 3 years S econd line 2004 -  2010
A Z T  + DDI + LP V /r A ll ch ild ren  fa iling  and 
E FV  based reg im en
S econd line 2004 -  2010
A Z T  + 3TC /A B C  + LP V /r A ll ch ild ren  fa iling  an 
E FV  based reg im en
S econd line 2010 -  2013
3TC  m onothe rapy 
(LM )**
In ch ild ren  fa iling  a firs t 
line reg im en tha t are 
unable  to take  a second 
line reg im en
H old ing  reg im en C urren tly
*  Treatment of adolescents was first mentioned in the 2010 Clinical Guidelines for the management of 
HIV & AIDS in adults and adolescents however the age groups for using different regimens, TDF over 
ABC, was only defined in the 2015 National Consolidated Guidelines18 23
**Not formally included in the South African ART guidelines however is used widely.24
For those with abnormal breast events, the total number of ART regimens patients 
had received were analysed. Other data analysed included baseline CD4 count and 
HIV-1 viral load (VL), all ART regimens prescribed, CD4 counts and HIV-1 VL at 
each regimen change, reasons for changing each regimen and the duration of each 
regimen. A change in ART regimen was defined as a change in any ARV in an 
adolescent’s regimen. This, however, did not include dosage adjustments or a 
change in the same drug’s formulation.
At the time of the first reporting of a breast abnormality, the total duration on ART as 
well as the length of time on the current regimen, ARV drugs prescribed as part of
the current regimen, the CD4 count and HIV-1 VL results (±3 months from the date 
that the breast event was first recorded) and the reported adherence were analysed. 
Reported adherence was categorised into none (<10% of doses taken), a few (10 -  
30% of doses taken), about half (30-60% of doses taken), most (60-90% of doses 
taken) and all (>90% of all doses taken). CD4 results were grouped for ease of 
analysis into four groups: <200 cells/gl; 200-500 cells/gl; 501 -1000 cells/gl; >1000 
cells/gl. HIV-1 VL results were similarly grouped into those considered to be 
suppressed at less than 50 copies/ml, those 50-1000 copies/ml and HIV-1 viral load 
results over 1000 copies/ml.
With regards to particular ARV drugs, the use of different individual drugs was 
compared for those with abnormal and normal breasts. Significant relationships 
between individual ART drugs and breast abnormalities were sought and 
significance established using the Fisher’s exact test of difference of proportions. For 
all abnormal breast cases, EFV and D4T exposure was tabulated as well as the 
median time of exposure to both calculated.
Clinical information surrounding the event such as pubertal development including 
Tanner staging, anthropometric measures particularly body mass index (BMI)
(kg/m2), and details of investigations and interventions performed were analysed. 
Existing co-morbidities including lipodystrophy (fat accumulation and lipoatrophy), 
hyperthyroidism, hypogonadism, obesity, liver failure and renal failure were 
specifically considered however any concurrent medical condition was included in 
the analysis. Concomitant medication use was also explored and the particular 
medications prescribed were analysed. The presenting breast condition and 
description of the breast as well as investigations and interventions for abnormal 
breast conditions were included in the analysis.
2.4. Data Analysis
All statistical analysis was done using STATA version 14 (Stata Corporation, College 
Station, Texas, USA).25 Medians and interquartile ranges were used to report 
descriptive statistics where appropriate. The prevalence of breast abnormality in this 
population of HIV-infected adolescents on ART was determined. Cases were 
categorised according to patient demographics, HIV and ART characteristics 
including the particular ART drugs and clinical measures around the time of the 
breast event. Statistically significant differences in the prevalence of breast 
abnormality by demographic and ART data were established.
Statistically significant associations between the patient characteristics extracted and 
abnormal breast conditions were tested using a Fisher’s exact test for difference in 
proportions (if count or categorized variable) and the Student’s t-test for difference of 
means (if continuous variable). Fisher’s exact test was chosen over the Pearson chi- 
squared test owing to the small numbers with breast conditions. A probability value 
of p<0.05 was designated for statistical significance.
2.5. Ethical considerations
Ethical clearance to perform this retrospective record review was sought from the 
University of Witwatersrand Human Research Ethics Committee (M141134). As data 
was collected retrospectively from medical records and no patient contact or patient 
follow-up was needed, informed consent for the participants of this study was not 
requested. There was no risk of patient confidentiality being breached as data 
collection forms contained no identifying information. There were no direct benefits to 
patients whose files were included in this study. Indirect benefits may be available as 
more information about managing breast conditions in adolescents on ART may be 
part of the outcome of this study.
3. Results
3.1. Patient characteristics
The number of records that were screened equalled 1376 and out of those 631 were 
eligible for inclusion in the study (45.9%). The basic demographics of the files 
reviewed are shown in table 3 (n=631). The median age for this study population 
was 14.0 years (IQR: 11.9 -16.0 years). More than half of the eligible files were from 
Clinic A (53.9%) and the rest were from Clinic B and C. There were more females in 
the cohort (1.05:1).
Table 3: All patients’ characteristics
C haracteris tics D escrip tion C o un t (% ) (n=631)
A ge M edian (IQ R ) years 14.0 (11 .9-16.0 )
C lin ic C lin ic  A 340 (53.9% )
C lin ic  B 102 (16.2% )
C lin ic  C 189 (30.0% )
Sex M ale 304 (48.2% )
Fem ale 322 (51.0% )
N ot recorded 5 (0.8% )
3.2. Patient HIV history
The regimens of only 554 files were available to be retrieved electronically. 
Collecting this data had not been part of the initial data collection plan for patients 
without breast abnormalities and therefore these details had be captured from the 
clinic electronic patient records once the manual file review was completed. As 
electronic capturing was not complete, not all regimens were available. All patients
with breast abnormalities, however, did have their ART regimens captured during the 
initial file review.
Details of ART regimens as well as individual ART drug exposures of all eligible 
patient files are shown in table 4 to 6. The most common regimen was a combination 
of ABC, 3TC and EFV (n=363, 65.5%). The next most commonly used regimen was 
LM (n=64, 11.6%).
3TC was the most commonly used NRTI in this population, with 96.2% of patients 
receiving 3TC or its analogue FTC as part of their regimen (n=533/554). ABC was 
the next most frequently used NRTI with 72.0% of patients receiving an ABC- 
containing regimen at the time of review (n=399/554). TDF is the third most 
commonly used NRTI (n=58, 10.5%) and the mean age of patients receiving this 
regimen was 16.8 years (Standard deviation (SD): 2.3 years) which was statistically 
significantly older than the rest of the studied cohort at the time of file review (n=13.8 
years, SD: 2.4; p<0.0005). This was followed by AZT (n=45, 8.1%) and D4T (n=11, 
2.0%).
The majority of patients were receiving NNRTI-based regimens (n=421,76.0%) 
when compared to PI-based regimens (n=60, 10.8%). The commonest NNRTI in use 
is EFV with 418 patients receiving it as part of combination ART at the time of 
censure (75.5%). The other NNRTI which was routinely in use was NVP (n=2, 0.4%) 
with one patient receiving RPV (0.2%).
With regards to PI regimens, 50 patients were receiving LPV/r (9.0%), the most 
common PI in use, and nine patients were receiving atazanavir/ritonavir (ATV/r)
(1.6%) with only one patient on darunavir/ritonavir (DRV/r) (0.2%).
Table 4: ART regimen for at the time of review for included records where regimen 
was retrieved (n=554)
A R T  R egim en C ount (% ) n=554
A B C + 3T C + E F V 363 (65.5)
LM 64 (11.6)
T D F + F T C /3T C + E F V 40 (7.2)
A B C + A Z T + L P V /r 17 (3.1)
A Z T + 3 T C + LP V /r 16 (2.9)
A B C + 3T C + L P V /r 9 (1.6)
O the r /  Incom ple te * 45 (8.1)
*Regimens that are not described in table 2 or have not been frequently used have been placed under 
Other/Incomplete.
Table 5: NRTI antiretroviral at the time of review for included records where regimen 
was retrieved
A R T D escrip tion C o un t (% ) (n=554)
NR TI* AB C 375 (67.7)
A Z T 21 (3.8)
D 4T 10 (1.8)
TD F 51 (9.2)
A B C  & D 4T 1 (0.2)
A B C  & A Z T 19 (3.4)
A B C  & TD F 2 (0.4)
A B C  & DDI 1 (0.4)
D 4T & DDI 1 (0.2)
TD F  & A Z T 4 (0.7)
A B C ,T D F ,A Z T 1 (0.2)
No o the r NRTI (inc ludes 
LM **)
68 (12.3)
*Lamivudine excluded as part of a suppressive ART regimen 
**Number of patients receiving LM = 64
Table 6: NNRTI or PI antiretroviral at the time of review for included records where 
regimen was retrieved (n=554)
A R T D escrip tion C o un t (% ) (n=554)
N N R TI Tota l 421 (76.0)
EFV 418 (75.5)
NVP 2 (0.4)
R PV 1 (0.2)
PI Tota l 60 (10.8)
LP V /r 50 (9.0)
A T V /r 9 (1.6)
D R V /r 1 (0.2)
Both N N R TI + PI 4 (0.7)
N eith er (inc ludes LM) 69 (12.5)
3.3. Prevalence of breast abnormalities
The number of files that reported any breast event was 52 (8.2%). Some patients 
had breast mentioned multiple times in the file with the total number of breast events, 
both normal and abnormal, adding to 60 for 52 patients of which 68.3% (41/60) of 
breast events were described as abnormal in 37 patients. The prevalence of the 
breast abnormalities reported in the cohort evaluated was 5.9% (n=37/631).
Breast events that were separated by a period of six months in the patient’s record, 
without mention in between, were considered to be separate events.
3.4. Demographic characteristics for abnormal breast events
Table 7 shows the patient and breast characteristics for those files in which 
abnormal breast events are recorded. Most abnormal breast events were reported in 
patients 10-15 years of age (68.3%, n=28). In our study population, only two patients
under 10 years old experienced breast abnormalities whereas 11 patients between 
15 and 19 years old experienced breast complaints.
Table 7: Demographic characteristics for breast events (n=41)
C haracteris tic D escrip tion C ount (%)
A ge at b reast even t (n=41) m edian (IQR) years 13.5 (12.1 - 15.6)
< 10 years 2 (4.9% )
10 - 15 years 28 (68.3% )
> 15 years 11 (26.8% )
3.5. HIV and ART characteristics for abnormal breast events
Table 8 looks at the HIV patient characteristics for those who had abnormal breast 
events reported. All patients with recorded abnormal breast conditions were on ART 
at the time of the reported event. Only 27.0% of patients with breast abnormalities 
had been exposed to three or more ART regimens prior to developing their breast 
condition (n=10/37) while the remaining 73.0% had received two regimens or less 
(n=27/37). The majority of patients had been taking antiretrovirals for three years or 
more (73.2%, n=30) and most had only been on their current regimen for a median 
of two years with the shortest time being 0.3 years or 112 days. An excess of two 
thirds of patients had CD4 counts higher than 500 (70.7%, n=29) and were 
virologically suppressed as defined by a viral load of 50 copies/ml or fewer (70.7%, 
n=29). Good adherence to ART, defined as patient or patient caregiver self-report 
that greater than 90% of doses were administered, was noted in 63.4% of the 
patients with abnormal breast conditions with five patients having defaulted ART at 
the time of breast abnormality.
Table 8: Patient HIV and ART characteristics for abnormal breast events (n=41)
C haracteris tic D escrip tion C o un t (% )
Y ears  on A R T  from  in itia tion  to m edian (IQR) = 4 .9  (1.8 - 6.6)
breast event < 1 3 (7.3)
1 8 (19.5)
2 2 (4.9)
3 3 (7.3)
>4 25 (61.0)
Y ears  on reg im en  lead ing to m edian (IQR) = 2 .0  (1.2 - 4.6)
breast event <1 7 (17.1)
1 12 (29.3)
2 6 (14.6)
3 5 (12.2)
>4 11 (26.8)
C D 4 count at breast m edian (IQR) = 708 .0  (439.0  -
event (ce lls /p l)* 957.0)
<200 4 (9.8)
200 -  500 8 (19.5)
500 -  1000 21 (51.2)
>1000 8 (19.5)
HIV-1 V ira l load at breast m edian (IQR) 176.5 (91.5  - 373.5)
event (cop ies/m l)* U ndetectab le  (<50) 29 (70.7)
V ira l load 50 -  1000 10 (24.4)
V ira l load >1000 2 (4.9)
R eported  a dh eren ce  to N one recorded 10 (24.4)
A R T G ood adherence 26 (63.4)
Lost to fo llow  up 5 (12.2)
*  Defined as test taken +/- three months from the visit date when breast event is recorded
3.6. Clinical and breast characteristics for abnormal breast events
Table 9 shows that there was a lack of information recorded about the pubertal stage 
of the adolescents with only four patients (9.8%) with abnormal breast conditions 
having Tanner staging mentioned in their file. Only one patient was recorded to 
have passed through menarche.
Three patients were reported to have normal breast development, one male and two 
females, which was later, at another visit, thought to be abnormal. With regards to 
the condition reported, enlargement of the breasts was most often recorded with 18 
cases of abnormal breasts receiving this description. Thirteen had a diagnosis of 
gynaecomastia, four a diagnosis of lipomastia and three a diagnosis of both 
lipomastia and gynaecomastia recorded in their file. Other recorded conditions were 
breast buds in two male patients and breast lump was noted in a single patient. For 
one patient there was no description of the breast/s recorded.
In 25 patients with abnormal breast conditions, there was no severity of the breast 
condition recorded in the file. For the remainder, two had early or small as their 
abnormal breast severity, eleven mild or moderate and only three were described as 
large or severe.
Eight of the patients were described as having bilateral breast changes whereas only 
five had a unilateral breast condition with 28 having no description of whether a 
single breast or both breasts were affected.
Table 9: Clinical information for abnormal breast events (n=41)
C haracteris tic D escrip tion C ount (% ) (n=41)
BM I (kg /m 2) m edian (IQR) 19.0 (16.9 - 20.4)
U nderw e igh t (<25th percentile ) 12 (29.2% )
N orm al (25th-75 th percen tile ) 21 (51.2% )
O ve rw e igh t (>75th percen tile ) 8 (19.5% )
T an n e r s tag ing  recorded Yes 4 (9.8% )
N orm al b reast d eve lopm en t 3 (7.3% )
M enarche 1 (2.4% )
D escrip tion  o f breast Enla rgem en t 18 (43.9% )
B reast buds 2 (4.9% )
G ynaecom astia 12 (29.2% )
L ipom astia 4 (9.8% )
G ynaecom astia / L ipom astia 3 (7.3% )
B reast lum p 1 (2.4% )
N one recorded 1 (2.4% )
S everity  o f breast cond ition* Early  /  sm all 2 (4.9% )
M oderate  /  m ild 11 (26.8% )
Severe  /  ve ry  large 3 (7.3% )
N one recorded 25 (61.0% )
U nila tera l /  B ila tera l U nila tera l 5 (12.2% )
B ila tera l 8 (19.5% )
N one recorded 28 (68.3% )
* Only single counts for each event taken, in case of multiple description of size from clinician, the 
largest size is taken
Figure 1 shows few patients were reported to be tending towards being overweight 
(n=8/41, 19.5%) which was defined as a BMI plotting over the 75th centile. Most 
having a normal BMI (n=21,48.8%), BMI between the 25th and 75th centiles or being 
underweight, less than the 25th centile (n=12/41,31.7%).
Male Female
•  BMI --------------- 25th percentile --------------- 50th percentile ---------------  75th percentile
Data for figure 1 was sourced from the Centers of Disease Control and Prevention website.26
Figure 1: BMI (kg/m2) scatter plot for breast events reported in male and female 
adolescents on ART (Male: n=27; Female: n=14)
3.7. Association of breast abnormalities to patient characteristics
Table 10 shows the characteristics of those patient files that had documented 
abnormal breast events compared to files that had normal breast or no mention of 
breast development or conditions. Patient age at the latest visit in the study period 
was significantly different, with those with breast abnormalities being older than the 
group with normal breasts (p<0.0005). There was no difference observed in the 
incidence of breast abnormalities across all three sites (p=0.622). There was a 
statistically significant difference in the prevalence of abnormal breast across sex 
with males reporting a higher prevalence (7.9%) compared to females (4.0%) (p 
=0.043).
Table 10: Association of breast abnormalities to patient demographics (n=631)
C haracteris tics P atien ts  w ith  
abn o rm al breast 
(n=37)
Patients  w ith  
norm al breast 
(n=594)
p-value
A ge (years) D uring fo llow -up  
M ean (SD)
15.5 (2.0) 14.0 (2.6) <0.0005
A t A R T  initia tion 
M ean (SD)
8.3 (4.2) 8.5 (4.3) 0.771
C lin ic C lin ic  A 19 (51.4% ) 321 (54.1% ) 0.622
C lin ic  B 8 (21.6% ) 94 (15.8% )
C lin ic  C 10 (27.0% ) 179 (30.1% )
Sex Fem ale 13 (35.1% ) 309 (52.0% ) 0.043
M ale 24 (64.9% ) 280 (47.1% )
3.8. Association of breast abnormalities to ART characteristics
Table 11 and 12 show the differences in ART drugs prescribed in those with 
abnormal breast events compared to those without breast concerns. In both groups, 
most patients were receiving ABC, combined with 3TC as their NRTI backbone. 
Among patients treated with ABC, 7.5% had a reported breast abnormality however 
this was not significant (n=28/375; p=0.363).
Table 11: NRTI antiretroviral for patients at the time of first abnormal breast event and 
for patients with no mention of breast or normal breast events (n=554)
A R T D escrip tion Tota l (n=554)* A b no rm al 
(n=37) 
C o un t (%)
N orm al o r no  
m ention  
(n=517) 
C o un t (% )
p value*
NRTI AB C 375 28 (7.5) 347 (92.5) 0.363
A Z T 21 1 (4.8) 20 (95.2) 0.998
D 4T 10 2 (20) 8 (80) 0.139
TD F 51 2 (3.9) 49 (96.1) 0.563
A B C  & D 4T 1 0 (0) 1 (100) 0.998
A B C  & A Z T 19 0 (0) 19 (100) 0.630
A B C  & TD F 2 1 (50) 1 (50) 0.129
A B C  & DDI 1 0 (0) 1 (100) 0.998
D 4T & DDI 1 1 (100) 0 (0) 0.067
TD F  & AZT 4 0 (0) 4 (100) 0.998
A B C ,T D F ,A Z T 1 0 (0) 1 (100) 0.998
Incom ple te  / 
o the r**
68 2 (2.9) 66 (97.1) 0.296
* Excluded those records for which regimen was not available (n=77) 
**Lamivudine excluded as part of a suppressive ART regimen
Among the 418 patients on EFV, there were 34 patients with abnormal breast events 
(8.1%), a statistically significant association (p=0.016). Of the remaining patients, two 
abnormal breast events occurred on LM with one occurring on an NRTI-only holding 
regimen. This prevalence of 4.3% was lower than the overall prevalence of abnormal 
breast events in the cohort but the difference was not statistically significant. For 
those patients taking LPV/r, no breast abnormalities were recorded and breast 
abnormalities were more commonly seen with other drugs (p=0.039).
Table 12: NNRTI or PI for patients at the time of first abnormal breast event and for 
patients with no mention or normal breast events (n=554)
Drug class A n tire tro v ira l Tota l (n=554) A bno rm al 
(n=37) 
C o un t (%)
N orm al o r no 
m ention  
(n=517) 
C ount (% )
p value
N N R TI EFV 418 34 (8.1) 384 (91.9) 0.016
NVP 2 0 2 (100) 0.998
R PV 1 0 1 (100) 0.998
PI LP V /r 50 0 50 (100) 0.039
A T V /r 9 0 9 (100) 0.998
D R V /r 1 0 1 (100) 0.998
Both N N R TI + PI 4 0 (0) 4 (100) 0.998
N either* 69 3 (4.3) 66 (95.7) 0.606
*Neither includes LM
Particular exposure to chosen ART drugs is shown in table 13. All patients with 
abnormal breast conditions had received EFV as part of a prior or current regimen. 
The median time of exposure to EFV was 5.5 years. Comparatively, almost 60% of 
those with abnormal breast conditions had been exposed to D4T with the median 
time of exposure of 4.9 years.
Table 13: EFV exposure for those patients with abnormal breast (n=37)
EFV exposure C ount (%) 37 (100% )
A ccu m u la tive  tim e on EFV m edian (IQR) 5.5yrs (3 .8-8.5)
based reg im en*
D 4T  exposure C ount (%) 22 (59.5% )
A ccu m u la tive  tim e on D 4T m edian (IQR) 4 .9yrs  (1 .8-7.2)
based reg im en**
* Measured up until first breast abnormality/change from EFV 
** Measured up until change from D4T
3.9. Management of adverse event
Table 14 shows the concomitant medication, comorbidities, investigations and 
interventions for patients with abnormal breast conditions. One or more concomitant 
medication was received by 61.0% of patients (n=25) and 73.8% had a co-morbidity 
(n=30), with over half having two or more comorbidities (n=23, 56.1%).
Co-morbid lipodystrophy was diagnosed in 46.3% of those with abnormal breast 
conditions (n=19), with nine of those patients being classified as having fat 
accumulation syndrome (22.0%).
Only three of the patients were investigated for their abnormal breast condition. One 
patient received sonography and two others had blood taken to be analysed. Of 
these, one was tested for their prolactin levels with no result recorded.
Nearly half of the patients received no intervention for their abnormal breast 
condition. The most common intervention was the substitution of EFV for another 
antiretroviral (n=16, 39.0%). In six instances other ART substitutions took place 
either at the same time as changing from EFV or separately. Diet and exercise and 
Tamoxifen, an anti-oestrogen drug, were prescribed for one patient each. Three
patients were seen at a specialised breast clinic and there were plans to refer a 
further two patients in the next year. Almost half of abnormal breast conditions 
received no intervention (n=20, 48.8%).
Table 14: Concomitant medication, comorbidities, investigations and interventions 
for abnormal breast events
C haracteris tic D escrip tion C ount (% ) (n=41)
C o nco m itan t m ed ica tions None 16 (39.0)
A t least one drug 7 (17.1)
2 - 4 d rugs 15 (36.6)
5 d rugs 3 (7.3)
C o-m orb id ities No com orb id ities 11 (26.8)
O n ly  1 com orb id ity 7 (17.1)
2 - 4 com orb id ities 18 (43.9)
5 com orb id ities 5 (12.2)
L ip o d ystro p h y  syndrom e Tota l w ith  lipodystrophy 19 (46.3)
L ipoa trophy 6 (14.6)
Fat accum ula tion  (FA) 9 (22.0)
No descrip tion 4 (9.8)
In vestigations Investiga tion  requested 3 (7.3)
S onography 1 (2.4)
B lood tests 2 (4.8)
In terven tions No prescribed  in tervention 20 (48.8)
In te rvention  prescribed 21 (51.2)
E FV  substitu tion 13 (31.7)
O the r A R T  change 3 (7.3)
E FV  and o the r substitu tion 3 (7.3)
D iet and exerc ise 1 (2.4)
T am ox ifen  p rescribed* 1 (2.4)
*Tamoxifen prescribed but not received (taken from the clinical notes)
Of the 19 patients who received an ART drug substitution, table 15 shows details of 
the drug substitution and whether the breast condition resolved following the 
substitution.
EFV was the ART drug most often targeted for change when a breast abnormality 
occurred (n=16/19, 84.2%), followed by D4T (n=5/19, 26.3%). In this population,
EFV was most often substituted for NVP (n=9, 47.3%) followed by LPV/r and ATV/r 
(n=2/41, 10.5%). Three patients received more than one drug substitution or 
cessation simultaneously. The only three cases of resolution of the breast condition 
following ART substitution were observed, with all three cases occurring in the EFV 
to NVP group. No association was found between the resolution of breast conditions 
and substitution with NVP (p=0.221). For all other cases, there was no recording of 
resolution of the breast abnormality (n=16, 84.2%)
Table 15: Details of ART substitution and whether resolution took place (n=19)
S ubstitu tion C ount (%) R eso lved*
EFV to  NVP 9 (47.3) 3
EFV to  L P V /r 2 (10.5) 0
EFV to  A T V /r 2 (10.5) 0
D 4T  to  A B C 3 (15.8) 0
EFV to  L P V /r and D 4T  to  TD F 1 (5.3) 0
EFV to  N VP, D 4T -D D I to  A B C 1 (5.3) 0
A B C -3T C -E F V  to  LM 1 (5.3) 0
* Implies resolved prior to 31 December 2014 (end of the study period)
4. Discussion
The clinics that were studied have large populations of adolescents receiving 
antiretroviral therapy with just under half of the files screened being those of 
adolescents, as opposed to children, receiving ART. With such large populations of 
patients, common side effects experienced in a particular age group become 
evident.
One such condition is breast abnormalities in those receiving ART. The prevalence 
of breast abnormalities in this cohort of HIV infected adolescents on ART was 5.9%. 
In male patients the prevalence was 7.9% which exceeds the background incidence 
of physiological gynaecomastia in adolescent males of 4%.5
Despite there being more girls included in the study, there were significantly more 
breast events seen in male patients. Breast abnormalities in males are easier to 
detect and define due to the “all or nothing” nature of the abnormalities; that is male 
patients are not expected to develop breasts and so, when they do, it is easily 
noticeable. In girls, breast development includes a spectrum of changes, which 
makes an abnormal event more difficult to define.274
A significant difference in age was observed and adolescents with breast 
abnormalities were older than those without breast conditions. This suggests that 
most abnormalities of the breast in HIV-infected adolescents on ART are 
experienced in mid-adolescence, at a median age of 15.5 years, which is somewhat 
later than physiological gynaecomastia in boys, which is seen to peak earlier 
between the ages of 13 and 14 years.5
The link between ART drugs and breast abnormalities has not been well established 
with different drugs and mechanisms being hypothesised for the development of 
breast conditions in HIV-infected individuals.
Various drugs such as D4T and AZT have well documented links to lipodystrophy 
and may in turn affect the development of breasts through the same mechanism.9 
However other drugs, such as EFV, have not been shown to be a significant cause 
lipodystrophy and yet have been postulated to cause breast conditions.813 This
suggests that there is more than one possible aetiology interacting to result in a 
similar outcome of abnormal breast conditions in patients receiving ART.
In this cohort of patients, most were receiving an NNRTI as opposed to a PI-based 
regimen which is expected in accordance with the recommended South African ART 
guidelines for first line ART.18 The most frequently used NNRTI was EFV and this 
was combined with ABC and 3TC, which is the recommended first line regimen in 
South Africa for children and adolescents 3 to 14 years of age, in 65.2% of cases.18 
ABC was not shown to be associated with abnormal breast development (p=0.363). 
This suggests that in the majority of patients who were receiving ABC/3TC/EFV, EFV 
remains the likely candidate for causing breast abnormalities.
LM was the second most popular choice for adolescents in this cohort, with 11.6% of 
patients receiving this monotherapy regimen. LM is used in those children and 
adolescents who have adherence difficulties on their first line regimen and are 
unable, due to social circumstances, to take a more demanding second line 
regimen.24 While patients on LM did experience abnormalities of their breasts, the 
prevalence of abnormal breast conditions was lower than that of the rest of the 
cohort making lamivudine an unlikely candidate for causing this phenomenon.
Patients on PIs are likely to be receiving a second line regimen after having failed a 
first line regimen with over 10% of included patients being on a PI-based regimen. 
With the advent of ART for children in the public sector in South Africa only occurring 
in 2004,22 relatively few individuals in this cohort would have been under three years 
of age at the time and therefore eligible for a PI-based regimen as their first line.22 
Indeed, the median age of initiation for both groups of patients in this cohort was 
over 8 years of age which suggests they were most likely started on an NNRTI as
their first line regimen in accordance with the guidelines at the time.22 This 
seemingly older age of ART initiation in vertically infected children could be 
explained the rollout of ART only taking place in South Africa in 2004 and the relative 
complexity of the childhood ART guidelines as well as difficulties of ART accessibility 
at the time.22
Almost a third of this cohort was treatment experienced having received three or 
more ART regimens. They therefore would have had an exposure to a variety of 
ARV drugs. However, it was reassuring that while many patients were treatment 
experienced, three quarters of patients were receiving an NNRTI and were, 
therefore, still effectively on first line ART.
At present there are four plausible mechanisms by which ARV drugs cause breast 
abnormalities: 1) oestrogen receptor activation by ARV drugs particularly EFV,61013 
2) immune reconstitution inflammatory syndrome (IRIS),8 3) lipodystrophy syndrome9 
and 4) hypogonadism.16
4.1. Oestrogen receptor activation by EFV
At the time of reporting of an abnormal breast event, receiving EFV was significantly 
associated with the development of breast abnormalities in this cohort of patients. 
Furthermore, all patients with abnormal breast conditions had received EFV as part 
of a previous regimen and their exposure was often long-term with the mean time of 
exposure being 5.5 years. EFV use was associated with the development of 
abnormal breast conditions in this adolescent population which is supported by other 
adolescent and adult studies with similar outcomes.161013
Resolution of abnormal breast conditions only occurred in three patients and all of 
these patients had been changed off EFV and started on NVP. This drug substitution
was the most commonly observed and other substitutions of EFV or other ART drugs 
occurred in numbers too small to show a trend. The failure to report that an 
abnormality resolved in the rest of those suffering from breast abnormalities led to 
uncertainty about whether other drug substitutions were effective. At least two 
patients were later referred to a specialised breast clinic suggesting no resolution. 
Further follow up of the affected patients may provide more answers as to whether 
the interventions were effective.
4.2. IRIS
The hypothesised mechanism of breast enlargement in IRIS is thought to be through 
an increased production of cytokines which increase breast tissue aromatase activity 
causing increased oestrogen production.8 Once full immune reconstitution has taken 
place, the levels of these cytokines fall, which should lead to full resolution.
The median time for receiving ART in this adolescent cohort was around five years 
and the median duration of their current ART regimen was two years. The majority of 
patients had a CD4 count greater than 500 at the time of their breast event. IRIS 
usually occurs in patients with lower baseline CD4 counts particularly those below 50 
cells/gl.15
Unlike in adults, the proximity of ART initiation to breast enlargement is often not as 
pronounced in adolescents. Adults appear to develop gynaecomastia within months 
of starting antiretroviral therapy,6 whereas the timing is less predictable in 
adolescents with most breast abnormalities occurring after years of treatment with 
the same regimen. This suggests that IRIS, which occurs within three months of 
starting ART, is unlikely to be the mechanism of abnormal breast formation in 
adolescents.14
4.3. Lipodystrophy
Lipodystrophy was by far the most common comorbidity seen in patients with breast 
abnormalities and has been attributed to be the cause of some cases of breast 
enlargement in adults on ART.9 Nearly half of those with abnormal breasts were 
reported to have comorbid lipodystrophy with fat accumulation being the most 
frequently reported feature followed by lipoatrophy. Lipodystrophy is often associated 
with D4T and AZT, however few patients in this study were on D4T- or AZT- 
containing regimens at the time of censure and very few breast events were 
documented while patients received regimens containing these drugs. Despite this 
almost 60% had received D4T as part of a previous regimen and had received the 
drug for a median duration of 4.9yrs (IQR: 1.8-7.2). D4T was found to be associated 
with the development of abnormal breasts (p=0.028), however the mechanism is 
most likely to be through fat accumulation as part of lipodystrophy. As only one 
patient was investigated by sonography, it is difficult to establish whether the breast 
abnormalities recorded are part of the spectrum of lipodystrophic changes, which 
may be mild and difficult to distinguish in their early stages, or isolated breast 
enlargement. Sonography is not available at primary healthcare facilities in South 
Africa and this may account for why very few patients were investigated using 
sonography (4.8%) and yet many more (51.2%) received an intervention for their 
breast condition.
4.4. Hypogonadism
The hypothesis in a case control study performed on a Spanish adult cohort was that 
that free testosterone levels in male patients with gynaecomastia on ART were 
significantly lower than a control group without breast abnormalities.13 None of the 
male patients in our adolescent cohort had free testosterone levels performed to rule
out hypogonadism as a cause for their breast abnormality. Although there was a 
comment made in one patient’s file regarding him receiving hormonal injections for 
hypogonadism, there were no other details provided as this condition was managed 
at another centre. As such it is difficult to draw any conclusions regarding 
hypogonadism as a modality causing breast abnormality in this cohort.
4.5. Adherence to Antiretroviral Therapy
Adherence to a prescribed treatment is generally difficult to assess. This is because 
patient / caregiver self-report is often the only modality available making 
measurement of adherence highly subjective. In many cases, self-report is 
strengthened by other objective measures such as the patient’s viral load, clinic 
attendance records and pill counts. Good adherence to ART was reported by 63.4% 
of patients with abnormal breast conditions. This is supported by rates of virological 
suppression defined as less than 50 copies/ml in an excess of 70% in this population 
subset. This suggests that good adherence to ART, which can be clinically verified, 
may be a contributory factor in the development of abnormal breast conditions in 
adolescents. A limitation was that there were no comparative HIV-1 viral load results 
collected from those without breast condition to determine whether virological 
suppression is associated with breast abnormalities.
A positive association between EFV and breast abnormalities however was 
observed and it may be postulated that a dose-dependent relationship, that is as 
increasing amounts of EFV are ingested more breast abnormalities may be 
observed, should be investigated further in a prospective case control study.
Five patients were reported to have been lost to follow up around the time of breast 
abnormality. They may have become aware, through their clinician, that the
abnormalities of their breasts could have been caused by their ART and had decided 
to stop medication of their own accord. The role of this potentially dire effect on 
treatment adherence needs further investigation.
4.6. Breast abnormalities
Nearly half of the cases of breast abnormality were described somewhat vaguely as 
enlargement and just less than half were described using the terms gynaecomastia 
and lipomastia, which appear to be used interchangeably. The prevalence of severe 
breast abnormalities for the whole population was 0.5% which was the same as the 
CHIPS cohort of child and adolescent patients on ART in the UK.1 Overall there 
appears to be a degree of indecision as to what is considered abnormal and what is 
considered part of the spectrum of normal adolescent breast development. Breasts 
could be described as abnormal by the clinician in a consultation to be later 
dismissed as normal by another. Below is an example from a patient file in the study:
"1st consultation: Possibly developing early gynaecomastia - watch (Doctor X)
2nd consultation: Concern(ed) previously about developing gynaecomastia but looks 
fine today (Doctor Y)
3rd consultation: Gynaecomastia improving (Doctor X)”
The grade of severity may also make it difficult to determine whether a change is 
normal or pathological with earlier cases frequently being confused with normal 
development. More severe conditions would be obvious and easier to grade. 
Although only two cases of abnormal breast development were detected early, it is 
likely that there were more early cases that were classed as normal or not detected. 
Cases of unilateral breast development would also be more easily classed as
abnormal compared to bilateral breast conditions which may be classed as normal 
breast development.
The severity of the breast condition was often disputed between clinicians with some 
choosing to intervene in a condition and others feeling the intervention would be 
more cumbersome to the patient than the distress caused by the condition. An 
example of this would be changing patient to a regimen with a high pill burden or 
increased medication frequency, which would adversely impact on adherence.
Other difficulties with the classification of breast abnormalities include the patient’s 
and clinician’s own beliefs of the severity of a breast condition. A patient’s attitude 
towards their breast condition, which may be based on the opinions of his family and 
friends, would influence his likelihood of reporting a suspected abnormality to a 
clinician. A patient may also be overly aware of a seemingly mild manifestation of 
gynaecomastia and request intervention even when the clinician feels that it is 
unwarranted. Similarly, a clinician may not prescribe an intervention, despite them 
believing the patient’s breast condition to be abnormal, if the patient does not feel 
that this is necessary.
Obtaining a definitive diagnosis of gynaecomastia or breast enlargement remains a 
challenge through the lack of available diagnostic modalities and expertise. 
Ultrasonography is able to assist with determining whether there is a glandular or 
fatty predominance, however this is not definitive.8 Coupled with the difficulty of 
obtaining an ultrasound, performed by a trained technician in the South African 
Primary Healthcare setting, this was not fully utilised as a modality to assist with 
appropriately managing patients with abnormal breast conditions.
There are classification systems used to grade the severity of gynaecomastia in 
male patients described by Simon et al28 and Rohrich et al29, however such systems 
exclude the detection of abnormalities in female patients. These examples highlight 
the need for an official and validated classification of the disorders of the breast seen 
in adolescents on ART to assist with diagnosis and management of such conditions.
4.7. Interventions for breast abnormalities
While over half of patients received an intervention (n=21/41), only three cases were 
reported to resolve. Of these patients, all three received an EFV to NVP substitution 
whereas no resolution was seen in patients with any other drug substitution, drug 
prescription or prescribed lifestyle changes. There was no association established 
between the resolution of abnormal breast events with substitution to NVP however 
this is most likely due to the small numbers of breast abnormalities and the limited 
study period.
While Tamoxifen, an anti-oestrogen drug used for treating gynaecomastia,510 was 
prescribed for one patient, the clinic did not stock the drug and thus it was never 
received by the patient. For this reason, Tamoxifen remains an unexplored 
intervention in this cohort.
Most patients’ breast abnormalities were not reported to resolve and very few were 
referred on to the next level of care. Three patients were referred to a specialised 
breast clinic where the recommendation was made for one female patient that 
continued observation of her breast size should be performed until the end of 
puberty. None of the three patients received a definitive intervention. This could be 
attributed to a lack of knowledge on how to manage these cases at a specialist level 
and further study is needed to develop the best treatment management algorithms.
4.8. Comorbidities and concomitant medication
There are several proposed conditions that may cause pathological gynaecomastia 
in adolescents and these include obesity, adrenal and testicular neoplasms, 
Klinefelter syndrome, Peutz-Jeghers syndrome, thyrotoxicosis, cirrhosis, primary 
hypogonadism, congenital adrenal hyperplasia, androgen insensitivity, malnutrition 
and particular medicines.5 The proposed mechanism of causality in adolescents is 
oestrogen excess which is able to activate oestrogen receptors in breast tissue.10 
One or more comorbidity was observed in almost three-quarters of patients with 
abnormal breast conditions. Lipodystrophy was noted in just under half of the 
patients.
One patient was recorded to be obese and lifestyle interventions, for example diet 
and exercise, were suggested for that patient in order to improve their breast 
condition. However the relationship between gynaecomastia and obesity is not well 
established with there being conflicting reports.5 Most patients (80%) had BMIs 
within the normal range or tending towards being underweight, with just under 20% 
tending to be overweight. This suggests that obesity as a cause of breast 
enlargement in this cohort is only a possible mechanism in less than a fifth of 
patients.
One other patient was reported to be receiving hormonal injections for 
hypogonadism. No investigations were performed for suspected other causes of 
breast abnormality in this study and this case stands in isolation.
Other concomitant medications may also contribute to the development of breast 
abnormalities with 6/10 patients having received one or more concomitant 
medication and over 4/10 receiving two or more concomitant medications. The high
levels of different drug exposures in this cohort may interfere with establishing a 
causal relationship between some drugs and breast development. For those drugs 
documented to cause gynaecomastia, only isoniazid, received by two patients, and 
hormonal injections, used by one patient, were seen in this cohort at the time of 
breast abnormality.7
5. Limitations
There was no opportunity, in this retrospective record review, to compare the 
frequency of breast abnormalities in this population with a similar control group 
(adolescents who are not HIV infected). Therefore, a background incidence of breast 
abnormalities in adolescents, particularly females, could not be established from 
which to perform a comparison. A prospective study will be needed to further 
investigate this.
Physical examination can be limited during patient visits in South African public 
health facilities providing ART. The onus is often on the patient to report their breast 
condition to the clinician before further enquiry will take place. This would have led to 
the reported incidence of breast abnormalities being lower than the actual incidence. 
As the issue of breast abnormalities in adolescents on ART becomes increasingly 
familiar to clinicians, there are likely to be more cases reported and referred for these 
issues. Therefore, a similar retrospective review a later year might reveal an 
increase in cases of breast conditions.
As this review did not extend to reviewing patient’s records who were less than 10 
years old in the study period (2014), a prevalence for breast abnormalities in patients 
less than 10 years old could not be commented on.
Little investigation took place into the cause of breast abnormalities in this cohort. 
The lack of availability of ultrasonography at primary healthcare level as well as the 
lack of the expertise required by a sonographer to adequately diagnose mild to 
moderate breast abnormalities and to distinguish between glandular and fatty breast 
predominance, would impact the diagnosis and, subsequent management, of these 
conditions. Blood tests were only performed in two patients and the results were 
thereafter not followed up. This is most likely due to a paucity of guidelines for 
clinicians to manage such conditions.
This record review was performed at three facilities among which the treating 
clinicians have substantial interaction and, therefore, may have similar algorithms for 
managing their patients. This may have affected the detection of cases, descriptions 
used; paucity of investigation as well as interventions used particularly those of drug 
substitution.
6. Conclusion
Children may be started on ART and could, after many years and only once they are 
in mid-adolescence, develop breast abnormalities. This discounts an IRIS 
phenomenon as a likely cause of abnormal breast development in adolescents. The 
timing however also does not correspond with the incidence of physiological 
gynaecomastia observed in male patients.5 While lipodystrophy was a common 
comorbidity in those with breast abnormalities, sonography was not routinely 
available to establish a definitive breast diagnosis. Similarly, the role of 
hypogonadism was not fully explored.
Being adherent to one’s ART regimen seemingly places patients at an increased risk 
of developing breast abnormalities. This negative result of good adherence to ART, 
in particular, needs to be consistently addressed by clinicians managing adolescents 
on ART, as it may lead to non-adherence in those patients previously taking their 
antiretrovirals correctly.
It is proposed that the drug choice for adolescent ART, particularly those regimens 
containing EFV, when interacting with the fluctuating hormonal levels during puberty, 
may account for this unique entity of breast abnormality. The role of EFV in the 
development of breast abnormalities in both male and female adolescents requires 
further exploration to determine the appropriate investigations to perform and the 
most effective interventions to employ.
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